[{"id":"3a8e94f4-0040-4f56-93f4-fd86db056dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06879041","created_at":"2025-06-07T14:42:17.891Z","updated_at":"2025-06-07T14:42:17.891Z","phase":"Phase 1","brief_title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06879041","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 03/10/2025","start_date":" 03/10/2025","primary_txt":" Primary completion: 04/16/2029","primary_completion_date":" 04/16/2029","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2025-06-04"},{"id":"067fae8a-0794-4faa-b039-26fcd91b764b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06842498","created_at":"2025-02-25T12:32:24.274Z","updated_at":"2025-02-25T12:32:24.274Z","phase":"Phase 2","brief_title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT06842498","lead_sponsor":"FibroGen","biomarkers":" CD46","pipe":"","alterations":" ","tags":["CD46"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FG-3246"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"9651d7d1-9259-4164-9a62-b578441ae0c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05730712","created_at":"2023-02-16T15:00:29.642Z","updated_at":"2025-02-25T12:29:24.132Z","phase":"Phase 2","brief_title":"Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05730712","lead_sponsor":"Mayo Clinic","biomarkers":" NRG1","pipe":"","alterations":" ","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/08/2024","start_date":" 03/08/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-20"},{"id":"a7bc76a3-7767-4569-b28f-313c198056ba","acronym":"MAGNITUDE","url":"https://clinicaltrials.gov/study/NCT03748641","created_at":"2021-01-18T18:22:54.153Z","updated_at":"2025-02-25T13:52:43.687Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03748641 - MAGNITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 765","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2025-02-20"},{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"74783677-e3f5-4018-b600-ee9dd649695b","acronym":"ST101-101","url":"https://clinicaltrials.gov/study/NCT04478279","created_at":"2021-01-18T21:30:28.794Z","updated_at":"2025-02-25T14:07:48.179Z","phase":"Phase 1/2","brief_title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04478279 - ST101-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" HR positive • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"76aa94db-cfe6-4048-bc32-6320bef5309a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06827080","created_at":"2025-02-25T14:44:58.708Z","updated_at":"2025-02-25T14:44:58.708Z","phase":"Phase 1/2","brief_title":"Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06827080","lead_sponsor":"Zhengguo Chen","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/11/2025","start_date":" 02/11/2025","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-14"},{"id":"cf2cfcd4-c077-4397-9d63-381c2282ddc5","acronym":"TATCIST","url":"https://clinicaltrials.gov/study/NCT05219500","created_at":"2022-02-05T18:28:39.147Z","updated_at":"2025-02-25T15:12:35.305Z","phase":"Phase 2","brief_title":"Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I\u0026T of Castration-resISTant Prostate Cancer (TATCIST).","source_id_and_acronym":"NCT05219500 - TATCIST","lead_sponsor":"Fusion Pharmaceuticals Inc.","biomarkers":" MSI • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FPI-2265"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-13"},{"id":"0fac5381-93dc-441c-92ea-772f08ac738a","acronym":"COROS","url":"https://clinicaltrials.gov/study/NCT06783127","created_at":"2025-02-25T15:46:11.570Z","updated_at":"2025-02-25T15:46:11.570Z","phase":"","brief_title":"Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT06783127 - COROS","lead_sponsor":"Santa Chiara Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 3000","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-11"},{"id":"b328f4e5-105e-4a5c-a45f-4777aede9baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457257","created_at":"2022-07-13T11:56:53.469Z","updated_at":"2025-02-25T16:17:55.903Z","phase":"Phase 4","brief_title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","source_id_and_acronym":"NCT05457257","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"dcba3c24-ec05-4fca-9279-f54be561571e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02769962","created_at":"2021-01-18T13:34:58.684Z","updated_at":"2025-02-25T16:36:43.308Z","phase":"Phase 1/2","brief_title":"Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer","source_id_and_acronym":"NCT02769962","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 05/09/2016","start_date":" 05/09/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-07"},{"id":"d6a707a3-bb85-4ce5-8066-8bc03501bcf5","acronym":"C-800-01","url":"https://clinicaltrials.gov/study/NCT03860272","created_at":"2023-03-25T19:00:32.588Z","updated_at":"2025-02-25T16:37:22.836Z","phase":"Phase 1","brief_title":"Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer","source_id_and_acronym":"NCT03860272 - C-800-01","lead_sponsor":"Agenus Inc.","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 499","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 01/13/2025","primary_completion_date":" 01/13/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-06"},{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"021a5f18-f5e7-498d-a188-e4903f2c76f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588609","created_at":"2022-10-20T14:11:50.019Z","updated_at":"2025-02-25T16:54:29.545Z","phase":"Phase 2","brief_title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","source_id_and_acronym":"NCT05588609","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-04"},{"id":"58481425-6a53-4802-b306-7ed470c87380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221542","created_at":"2021-01-18T20:32:52.184Z","updated_at":"2025-02-25T16:52:48.663Z","phase":"Phase 1","brief_title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04221542","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 08/17/2028","study_completion_date":" 08/17/2028","last_update_posted":"2025-02-04"},{"id":"877e6060-0685-49ad-bf87-696fb090b715","acronym":"","url":"https://clinicaltrials.gov/study/NCT03218826","created_at":"2021-01-18T15:52:53.855Z","updated_at":"2025-02-25T16:51:57.310Z","phase":"Phase 1","brief_title":"PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03218826","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PTEN • PIK3CB","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AZD8186"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 07/25/2022","primary_completion_date":" 07/25/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-04"},{"id":"971ccbcc-807b-4f19-a719-95e21b179631","acronym":"C4551001","url":"https://clinicaltrials.gov/study/NCT04606446","created_at":"2021-01-19T20:31:32.792Z","updated_at":"2025-02-25T16:53:21.614Z","phase":"Phase 1","brief_title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04606446 - C4551001","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER • CDKN2A","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 08/13/2025","primary_completion_date":" 08/13/2025","study_txt":" Completion: 03/07/2027","study_completion_date":" 03/07/2027","last_update_posted":"2025-02-04"},{"id":"f0fc4400-5658-46d6-a170-25551f795dfc","acronym":"LORIKEET","url":"https://clinicaltrials.gov/study/NCT05848011","created_at":"2023-05-08T15:03:53.392Z","updated_at":"2025-02-25T17:02:35.494Z","phase":"Phase 2","brief_title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05848011 - LORIKEET","lead_sponsor":"MacroGenics","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • lorigerlimab (MGD019)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-02-03"},{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"e9087e98-84d9-4794-8123-a03a7c489eac","acronym":"CHAARTED2","url":"https://clinicaltrials.gov/study/NCT03419234","created_at":"2025-02-25T17:35:55.932Z","updated_at":"2025-02-25T17:35:55.932Z","phase":"Phase 2","brief_title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","source_id_and_acronym":"NCT03419234 - CHAARTED2","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 04/26/2018","start_date":" 04/26/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-29"},{"id":"9b1c2dc1-3b24-43f9-b184-70bf85aad83b","acronym":"NCI-2018-01648","url":"https://clinicaltrials.gov/study/NCT03682289","created_at":"2021-01-18T18:03:10.694Z","updated_at":"2025-02-25T15:07:56.671Z","phase":"Phase 2","brief_title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03682289 - NCI-2018-01648","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI • ATM • ARID1A • UGT1A1","pipe":" | ","alterations":" ATM mutation","tags":["MSI • ATM • ARID1A • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-28"}]